
Announcing the first stem cell translational journal.

STEM CELLS TRANSLATIONAL MEDICINE

© AlphaMed Press



Call for Papers

www.StemCellsTM.com



Call for Papers

AlphaMed Press is proud to launch STEM CELLS TRANSLATIONAL MEDICINE, a highly visible and high impact forum dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.

Mission

By bridging stem cell research and clinical trials, STEM CELLS TRANSLATIONAL MEDICINE will help move applications of critical investigations closer to accepted best practices. SCTM answers an acknowledged need within the research and clinical communities for comprehensive and cohesive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigations.

Stem cells therapies and regenerative medicine have both a provocative and powerful potential—offering the distinct possibility of eventually repairing or replacing tissues damaged from disease, including certain cancers. By helping to speed expert translations of emerging discoveries from the laboratory into legitimate clinical trials and finally bedside applications, STEM CELLS TRANSLATIONAL MEDICINE ultimately should improve patient outcomes.

Focusing on major advances in the field, STEM CELLS TRANSLATIONAL MEDICINE will publish high-impact, peer-reviewed articles in the following categories.

- Original research articles that:
 - Bridge progenitor and stem cell research into preclinical and clinical studies.
 - Help to speed expertly executed translations of emerging lab discoveries into well-controlled clinical trials and bedside application.
 - Significantly advance the clinical utilization of progenitor and stem cell molecular and cellular biology.
 - Decipher mechanisms of progenitor cells, stem cells, and cancer stem cells, pluri-/multi-potency and targeted differentiation of stem cells, scale-up and engineering, trafficking, engraftment and assaying effects of stem cells under in vitro and in vivo conditions for translational use.
 - Address the process of progenitor and stem cell clinical trial design, regulatory and ethical approval, and implementation.



- Review articles relevant to the translation of progenitor and stem cell technologies.
- Original, first-in-human case studies relevant to translational medicine.
- Negative results from clinical trials important to the field but often underreported.



Anthony J. Atala, MD

Editors

AlphaMed Press is delighted to announce that Dr. Anthony J. Atala, a world-renowned leader in translational and regenerative medicine and currently Director of the Institute of Regenerative Medicine in Winston-Salem, NC, joins STEM CELLS TRANSLATIONAL MEDICINE as its Founding Editor.

Dr. Doug Losordo (Director, Program in Cardiovascular Regenerative Medicine and Director, Feinberg Cardiovascular Research Institute at Northwestern University) joins as Associate Editor. Other Associate Editors to be announced.

Availability

STEM CELLS TRANSLATIONAL MEDICINE will be available online December 2011 and in print January 2012.

Send pre-submission inquiries to Editor@StemCellsTM.com

CIRM's Support

The California Institute for Regenerative Medicine (CIRM) will provide a three-year seed grant in support of the publication of SCTM.

www.StemCellsTM.com



STEM CELLS TRANSLATIONAL MEDICINE Editorial Office
AlphaMed Press | 318 Blackwell Street | Durham, NC 27701
Phone: 919.680.0011 | Fax: 919-680.4411 | e-mail: Editors@StemCellsTM.com

Coming soon, the Stem Cells Translational Medicine App.



Sister Journal

AlphaMed Press



The International Journal of Cell Differentiation and Proliferation

